Topics:

Interleukin-11 to Enter Phase III

Interleukin-11 to Enter Phase III

CAMBRIDGE, Mass--In a phase II study, Genetics Institute's recombinant human interleukin-11 (rhIL-11) restored platelets in throm-bocytopenic patients undergoing cancer chemotherapy to the extent that significantly fewer rhIL-11 treated patients required platelet transfusions, compared to placebo.

Based on this favorable outcome, the company plans to begin a phase III study by the end of this year.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.